Role of angiogenesis and angiogenic factors in colorectal cancer

Central-European Journal of Immunology

Volumn 34, Issue 4, 2009, Pages 254-260

  Bałan, Barbara J ^a   SŁotwiński, Robert ^a,b   Skopinska Rozewska E W A ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Angiogenesis; Angiogenic factors; Colorectal cancer; VEGF

Indexed keywords

ANGIOGENIC FACTOR;

ANGIOGENESIS; CARCINOGENESIS; CAUSE OF DEATH; COLORECTAL CANCER; HUMAN; ONCOGENE; PHENOTYPE; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 75349093747     PISSN: 14263912     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. www.coloncancer.about.com/od/stagesandsurvivalrates/
2. O'Connell JB, Maggard MA, Ko CY (2004): Colon cancer survival rates with the new American Joint Committee on Cancer Sixth Edition Staging. J Natl Cancer Inst 96: 1420-1425.
3. Carmeliet P (2005): Angiogenesis in life, disease and medicine. Nature 438: 932-36.
4. Ferrara N, Kerbel RS (2005): Angiogenesis as therapeutic target. Nature 438: 967-74.
5. Kerbel RS, Folkman J (2002): Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-39.
6. Ferrara N (2004): Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
7. American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008 http://www.gi.org/media/releases/ACG2009CRCGuideline.pdf
8. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG (1993): Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 85: 1311-1318.
9. Levin B, Lieberman DA, McFarland B (2008): Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134: 1570-1595.
10. NHS Bowel Cancer Screening Programme. www.cancerscreening.nhs.uk
11. Burch JA, Soares-Weiser K, St John DJ et al. (2007): Diagnostic accuracy of fecal occult blood tests used in screening for colorectal cancer. A systematic revive. J Med Screen 3: 132-137.
12. Tagore KS, Lawson MJ, Yukaitis JA et al. (2003): Sensitivity and specificity of stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 3: 47-53.
13. Thun MJ, Calle EE, Namboodiri MM et al. (1992): Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst 84: 1491-1500.
14. Hardy RG, Meltzer SJ, Jankowski JA, ABC of Colorectal Cancer (2000): Molecular basis for risk factors. BMJ 321: 886-889.
15. Schatzkin A, Lanza E, Corle D et al. (2000): Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. N Engl J Med 342: 1149-1155.
16. Narodowy Program Zwalczania Chorób Nowotworowych http//: www.mz.gov.pl
17. Toomey DP, Murphy JF, Conlon KC (2009): COX-2, VEGF and tumour angiogenesis. Surgeon 7: 174-180.
18. Gately S, Kerbel R (2003): Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 37: 179-192.
19. Grayson T (2004): Colon cancer review. Annual Oncology Service Line Report 12/05.
20. Moon Y, Bottone FG, McEntee MF, Eling T (2005): Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by trombospondin-1 via the early grow response gene Egr1. Mol Canc Ter 4: 1551-1558.
21. Richter M, Weiss M, Weinberger I et al. (2001): Growth inhibition and induction of apoptosis in colorectal tumor cells, by cyclooxygenase inhibitors. Carcinogenesis 22: 17-25.
22. Graca B, Lunet C, Coelho AS et al. (2004): Angiogenesis in cancer: from biopathology to therapy. Accta Med Port 17: 76-93.
23. Wang L, Chen W, Xie X (2008): Celecoxib inhibits tumor growth and angiogenesis in an orthotropic implantation tumor model of human colon cancer. Exp Oncol 30: 42-51.
24. Crew TE, Elder DJ, Paraskeva C (2000): A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Carcinogenesis 21: 69-77.
25. Shtivelband MI, Juneja HS, Lee S, Wu KK (2003): Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression. J Thromb Haemost 1: 2225-2233.
26. Giardiello FM, Offerhause GJ, DuBois RN (1995): The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer 31A: 1071-1076.
27. Neugut AI. (2009): Aspirin as adjuvant therapy for colorectal cancer: a promising new twist for an old drug. JAMA 302: 688-689.
28. Voutsadakis IA (2007): Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitinproteasome system and Cox-2. J Cell Mol Med 11: 252-285.
29. Shachaf CM, Flesher DW (2005): Rehabilitation of cancer through oncogene inactivation. Trends Mol Med 11: 316-321.
30. Folkman J, Ryeom S (2005): Is oncogene addiction angiogenesis-dependent? Cold Spring Harb Symp Quant Biol 70: 389-97.
31. Flesher DW (2008): Tumor dormancy and oncogene addiction. APMIS 116: 629-637.
32. Miyaki M, Yamaguchi T, Iijima T et al. (2008): Difference in characteristics of APC mutations between colonic and extracolonic tumors of FAP patients: variations with phenotype. Int J Cancer 122: 2491-2497.
33. Chiang JM, Chen HW, Tang RP et al. (2009): Mutation analysis of the APC gene in Taiwanese FAP families: low incidence of APC germline mutation in a distinct subgroup of FAP families. Fam Cancer 19: [Epub ahead of print].
34. Heinen CD (2009): Genotype to phenotype: Analyzing the effects of inherited mutations in colorectal cancer families. Mutat Res Sep 17: [Epub ahead of print].
35. http://www.hopkinsgi.org/GDL-Disease.aspx?CurrentUDV=31&GDL-Disease- ID=5F8BA0A9-ACCC-43B8-9815-7976ABA08EE2&GDL-DC-ID=D03119D7-57A3-4890-A717- CF1E7426C8BA
36. Lynch HT, Lynch JF, Attard TA (2009): Diagnosis and management of hereditary colorectal cancer syndromes: Lynch syndrome as a model. CMAJ 181: 273-280.
37. Ponz de Leon M, Percesepe A (2001): Pathogenesis of colorectal cancer. Digest Liver Disease 32: 807-821.
38. Phelps RA, Broadbent TJ, Stafforini DM, Jones DA (2009): New perspectives on APC control of cell fate and proliferation in colorectal cancer. Cell Cycle 15: 2549-2556.
39. Chen HM, Fang JY (2009): Genetics of the hamartomatous polyposis syndromes: a molecular review. Int J Colorectal Dis 24: 865-874.
40. Claessen MM, Lutgens MW, van Buuren HR et al. (2009): More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 15: 1331-1336.
41. Tejpar S, Piessevaux H, Claes K et al. (2007): Magnesium wasting associated with epidermal-growth-factor receptortargeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 8: 387-394.
42. Slattery ML, Benson J, Curtin K et al. (2000): Carotenoids and colon cancer. Am J Clin Nutr 71: 575-582.
43. Michels KB, Giovannucci E, Joshipura KJ et al. (2000): Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Inst 92: 1740-1752.
44. Flood A, Schatzkin A (2000): Colorectal cancer: does it matter if you eat your fruits and vegetables? J Natl Cancer Inst 92: 1706-1707.
45. Bonithon-Kopp C, Kronborg O, Giacosa A et al. (2000): Calcium and fiber supplementation in prevention of colorectal adenoma recurrence: a randomized intervention trial. European Cancer Prevention Organisation Study Group. Lancet 356: 1300-1306.
46. Giovannucci E, Colditsz GA, Stampfer MJ, Willett WC (1996): Physical activity, obesity, and risk of colorectal adenoma in women (United States). Cancer Causes Control 7: 253-263.
47. Folkman J (2007): Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
48. Folkman J (2007): Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg 42: 1-11.
49. Folkman J, Merler E, Abernathy C, Williams G. (1971): Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133: 275-288.
50. Folkman J (1971): Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
51. Messersmith WA, Ahnen DJ (2008): Targeting EGFR in colorectal cancer. N Engl J Med 359: 1834-1836.
52. Chu E (2008): Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression. Clin Colorectal Cancer 7: 162.
53. Mendelsohn J, Baselga J (2003): Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799.
54. Lurje G, Zhang W, Schultheis AM et al. (2008): Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 19: 1734-1741.
55. Kim KJ, Li B, Winer J et al. (1993): Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
56. Kaminska J, Nowacki MP, Kowalska M et al. (2005): Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type 1 - an independent prognostic factor. Tumour Biol 26: 186-194.
57. Albanes D, Malila N, Taylor PR et al. (2000): Effects of supplemental a-tocopherol and beta-carotene on colorectal cancer: results from a controlled trial (Finland). Cancer Causes Control 11: 197-205.
58. Karl E, Warner K, Zeitlin B et al. (2005): Bcl-2 acts in a proangiogenic signaling pathway through nuclear factorkappaB and CXC chemokines. Cancer Research 65: 5063-5069.
59. Acosta JC, Gil J (2009): A role for CXCR2 in senescence, but what about in cancer? Cancer Res 69: 2167-2170.
60. Acosta JC, O'Loghlen A, Banito A et al. (2008): Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 13; 133: 1006-1018.
61. Osarogiagbon RU, Sachdev JC, Khattak AG, Kronish LE (2009): Pattern of use of adjuvant chemotherapy for stage II colon cancer: a single-institution experience. Clin Colorectal Cancer 8: 94-99.
62. Mainwaring P (2006): Angiogenesis inhibitors in cancerclinical applications. Exp Clin Oncol Aust Prescr 29: 13-15.
63. Chau I, Cunningham D (2009): Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 100: 1704-1019.
64. Eichhorn ME, Kleespies A, Angele MK et al. (2007): Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg 392: 371-379.
65. Quirke P, Williams GT, Ectors N et al. (2007): The future of the TNM staging system in colorectal cancer: time for a debate? Lancet Oncol 8: 651-657.
66. Greene FL (2007): Current TNM staging of colorectal cancer. Lancet Oncol 8: 572-573.
67. Naschberger E, Croner RS, Merkel S et al. (2008): Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy. Int J Cancer 123: 2120-2129.
68. Giatromanolaki A, Sivridis E, Koukourakis MI (2006): Angiogenesis In colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol 29: 408-417.
69. Pang RW, Poon RT (2006): Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag 2: 97-108.
70. Elfiky AA, Saif MW (2007): The developing trend of monoclonal antibodies in the treatment of colorectal cancer. Expert Opin Biol Ther 7: 871-883.
71. Goh V, Padhani AR, Rasheed S (2007): Functional imaging of colorectal cancer angiogenesis. Lancet Oncol 8: 245-255.
72. Hurwitz H (2004): Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 4: S62-S68.
73. Karl E, Zhang Z, Dong Z et al. (2007): Unidirectional crosstalk between Bcl-xL and Bcl-2 enhances the angiogenic phenotype of endothelial cells. Cell Death Differ 14: 1657-1666.
74. Warner KA, Miyazawa M, Cordeiro MM et al. (2008): Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia 10: 131-139.
75. Nör JE, Christensen J, Mooney DJ, Polverini PJ (1999): Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154: 375-384.
76. Zetter BR (1998): Angiogenesis and tumor metastasis. Annu Rev Med 49: 407-424.
77. Frank R, Saclarides T, Leurgans S, Rubin BD et al. (1995): Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 222: 695-699.
78. Cai SR, Zheng S, Zhang SZ (2005): Multivariate analysis of prognostic factors in colorectal cancer patients with different ages. Zhonghua Zhong Liu Za Zhi 27: 483-485.
79. Stoeltzing O, Liu W, Reinmuth N et al. (2003): Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Annals Surg Oncol 10: 722-733.
80. Morabito A, De Maio E, Di Maio M et al. (2006): Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11: 753-764.
81. Eche N, Pichon MF, Quillien V et al. (2001): Standards, options and recommendations for tumor markers in colorectal cancer. Bull Cancer 88: 1177-1206.
82. Cristi E, Perrone G, Toscano G et al. (2005): Tumor proliferation angiogenesis and ploidy status in human colon cancer. J Clin Pathol 58: 1170-1174.
83. Lee JC, Chow NH, Wang ST, Huang SM (2000): Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36: 748-753.
84. Takahashi Y, Kitadai Y, Bucana CD et al. (1995): Angiogenic targeting for colorectal cancer. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964-3968.
85. Kumar H, Heer K, Lee PW et al. (1998): Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 4: 1279-1285.
86. Ciardiello F, Tortora G (2008): EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174.